Strategic Financial Concepts LLC Acquires Shares of 13,360 NeoGenomics, Inc. (NASDAQ:NEO)

Strategic Financial Concepts LLC acquired a new stake in NeoGenomics, Inc. (NASDAQ:NEO) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 13,360 shares of the medical research company’s stock, valued at approximately $220,000.

A number of other hedge funds have also recently added to or reduced their stakes in the company. Fernwood Investment Management LLC boosted its position in shares of NeoGenomics by 1.0% during the third quarter. Fernwood Investment Management LLC now owns 89,500 shares of the medical research company’s stock valued at $1,320,000 after buying an additional 900 shares during the last quarter. FMR LLC boosted its position in shares of NeoGenomics by 7.6% during the third quarter. FMR LLC now owns 13,255 shares of the medical research company’s stock valued at $196,000 after buying an additional 931 shares during the last quarter. Blue Trust Inc. boosted its position in shares of NeoGenomics by 42.3% during the third quarter. Blue Trust Inc. now owns 3,318 shares of the medical research company’s stock valued at $46,000 after buying an additional 987 shares during the last quarter. KBC Group NV boosted its position in shares of NeoGenomics by 33.1% during the third quarter. KBC Group NV now owns 4,530 shares of the medical research company’s stock valued at $67,000 after buying an additional 1,127 shares during the last quarter. Finally, Versant Capital Management Inc boosted its position in shares of NeoGenomics by 174.9% during the fourth quarter. Versant Capital Management Inc now owns 1,795 shares of the medical research company’s stock valued at $30,000 after buying an additional 1,142 shares during the last quarter. Institutional investors and hedge funds own 98.50% of the company’s stock.

NeoGenomics Price Performance

NeoGenomics stock opened at $11.10 on Friday. NeoGenomics, Inc. has a 52 week low of $10.69 and a 52 week high of $19.11. The business has a 50-day simple moving average of $15.28 and a 200 day simple moving average of $15.49. The company has a quick ratio of 1.91, a current ratio of 1.98 and a debt-to-equity ratio of 0.38. The stock has a market cap of $1.43 billion, a price-to-earnings ratio of -17.90 and a beta of 1.23.

NeoGenomics (NASDAQ:NEO) last posted its earnings results on Tuesday, February 18th. The medical research company reported ($0.02) EPS for the quarter, missing the consensus estimate of $0.03 by ($0.05). NeoGenomics had a negative return on equity of 2.10% and a negative net margin of 11.92%. The business had revenue of $172.00 million for the quarter, compared to analysts’ expectations of $173.40 million. On average, research analysts forecast that NeoGenomics, Inc. will post -0.05 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on the company. Jefferies Financial Group assumed coverage on NeoGenomics in a research report on Tuesday, December 10th. They issued a “buy” rating and a $22.00 price objective on the stock. The Goldman Sachs Group cut their price objective on NeoGenomics from $20.00 to $18.00 and set a “buy” rating on the stock in a research report on Tuesday, January 28th. Needham & Company LLC cut their price objective on NeoGenomics from $19.00 to $18.00 and set a “buy” rating on the stock in a research report on Wednesday. Benchmark cut NeoGenomics from a “buy” rating to a “hold” rating in a research report on Monday, January 13th. Finally, Bank of America cut their price objective on NeoGenomics from $19.00 to $16.00 and set a “neutral” rating on the stock in a research report on Wednesday. Two analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to MarketBeat, NeoGenomics currently has an average rating of “Moderate Buy” and an average price target of $19.80.

NeoGenomics Company Profile

NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.